ProQR Therapeutics NV reports results for the quarter ended in June - Earnings Summary

ProQR Therapeutics NV

03/08/2023 14:35

* ProQR Therapeutics NV  PRQR.OQ  reported a quarterly
adjusted
loss of 10 cents​​ per share for the quarter ended in June. The
mean expectation of seven analysts for the quarter was for a
loss of 11 cents per share.
    * Revenue rose 17.6% to €1.21 million from a year ago;
analysts
expected €1.22 million. 
    * ProQR Therapeutics NV's reported EPS for the quarter was a
loss
of 10 cents​.
    * The mean earnings estimate of analysts had risen by
about 12% in
the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company. 
    * ProQR Therapeutics NV shares had fallen by 8.6% this
quarter and
lost 60.0% so far this year.
    * The company reported a quarterly loss of €7.99 million.
    * Wall Street's median 12-month price target for ProQR
Therapeutics NV is $4.75 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," 3
"hold" and no "sell" or "strong sell." 

This summary was machine generated from LSEG Refinitiv data
August 3 at 01:34 p.m. UTC. ​All figures in euros unless
otherwise stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Jun. 30 2023      -0.11          -0.10          Beat
 Mar. 31 2023      -0.12          -0.11          Beat
 Dec. 31 2022      -0.18          -0.16          Beat
 Sep. 30 2022      -0.21          -0.34          Missed